SCHEMBL7185586

SCHEMBL7185586

CC(C)(C)c1cc(C(C)(C)C)c(C(=O)P(=O)(C(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c2ccccc2)c(C(C)(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.41
PTPN5 P54829 1/20 0.38
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALOX5 P09917 1/20 0.36
PTGS2 P35354 1/20 0.36
PGK1 P00558 1/20 0.35
PGK2 P07205 1/20 0.35
ACHE P22303 1/20 0.35
KCNK9 Q9NPC2 2/20 0.35
KCNK3 O14649 1/20 0.34
TRPV1 Q8NER1 3/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180834 0.91 NPSR1 (0.37) NPSR1PTPN5GAAMEN1KMT2A
SCHEMBL7181473 0.86 NPSR1 (0.39) NPSR1GAAMEN1KMT2AALOX5
SCHEMBL7183900 0.85 MEN1 (0.39) NPSR1GAAMEN1KMT2AALOX5
SCHEMBL7182622 0.85 NPSR1 (0.41) NPSR1GAAMEN1KMT2AALOX5
SCHEMBL7185487 0.82 CA12 (0.41) NPSR1PTPN5GAAMEN1KMT2A
SCHEMBL7189845 0.82 LMNA (0.37) NPSR1GAAMEN1KMT2AALOX5
SCHEMBL7175290 0.81 ALDH1A1 (0.39) NPSR1GAAKCNK9KCNK3LMNA
SCHEMBL7181415 0.81 TAS2R14 (0.41) NPSR1GAAKCNK9KCNK3HDAC6
SCHEMBL7186797 0.81 RAB9A (0.39) NPSR1GAAMEN1KMT2AALOX5
SCHEMBL7186785 0.81 LMNA (0.44) NPSR1GAAMEN1KMT2AKCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NPSR1 2669/4885PTPN5 799/4885GAA 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.